PAR · SAN.PA
Sanofi
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
Loading market information…
PAR · VETO.PA · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Vetoquinol S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Vetoquinol S.A.’s forward annual dividend is €0.93 per share, paid annual. The forward yield is 1.05% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Vetoquinol S.A.’s next earnings report is currently expected on Mar 25, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vetoquinol S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Americas, and the Asia Pacific regions. The company's diverse product portfolio addresses crucial therapeutic areas, including mobility, pain management, and inflammation; dermatological care and hygiene; anti-parasitic treatments; udder health; infectious disease control; reproductive solutions; behavior modification; internal medicine; and cardiovascular-renal support. These offerings cater to a wide spectrum of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside companion animals like dogs. Founded in 1933, Vetoquinol S.A. is headquartered in Lure, France, and functions as a subsidiary of Soparfin SCA.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| €269.02M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
€178.20+€0.50 (+0.28%)
EssilorLuxottica S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.97% below the high.
€228.40+€7.00 (+3.16%)
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
€155.80+€2.90 (+1.9%)
Ipsen S.A.’s quoted price sits in the upper half of its reported 52-week range, 10.46% below the high.
€90.15-€0.85 (-0.93%)
bioMérieux S.A.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
€344.50-€3.00 (-0.86%)
Virbac S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.55% below the high.
€0.81+€0.00 (+0.25%)
Euroapi S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.22% below the high.
€0.55+€0.01 (+1.11%)
AB Science S.A.’s quoted price sits in the lower half of its reported 52-week range, 65.96% below the high.
